195 related articles for article (PubMed ID: 33156579)
1. INSM1 immunostaining in solid papillary carcinoma of the breast.
Kudo N; Takano J; Kudoh S; Arima N; Ito T
Pathol Int; 2021 Jan; 71(1):51-59. PubMed ID: 33156579
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast.
Seijnhaeve E; Galant C; Van Bockstal MR
Int J Surg Pathol; 2021 Aug; 29(5):496-502. PubMed ID: 33426999
[TBL] [Abstract][Full Text] [Related]
3. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
[TBL] [Abstract][Full Text] [Related]
4. Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56.
Chen JF; Yang C; Sun Y; Cao D
Pathol Res Pract; 2020 Jun; 216(6):152993. PubMed ID: 32381384
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast.
Yanai H; Ishida M; Yoshikawa K; Tsuta K; Sekimoto M; Sugie T
Oncol Lett; 2022 Apr; 23(4):137. PubMed ID: 35317025
[TBL] [Abstract][Full Text] [Related]
6. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections.
Mukhopadhyay S; Dermawan JK; Lanigan CP; Farver CF
Mod Pathol; 2019 Jan; 32(1):100-109. PubMed ID: 30154579
[TBL] [Abstract][Full Text] [Related]
7. INSM1 Is Less Sensitive But More Specific Than Synaptophysin in Gynecologic High-grade Neuroendocrine Carcinomas: An Immunohistochemical Study of 75 Cases With Specificity Test and Literature Review.
Zou Q; Zhang L; Cheng Z; Guo X; Cao D
Am J Surg Pathol; 2021 Feb; 45(2):147-159. PubMed ID: 33264139
[TBL] [Abstract][Full Text] [Related]
8. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
9. Insulinoma-associated protein 1 (INSM1) expression in breast carcinomas with neuroendocrine morphologies: application and future prospective.
Kawasaki T; Kaira K
Virchows Arch; 2021 Jul; 479(1):191-194. PubMed ID: 33025295
[TBL] [Abstract][Full Text] [Related]
10. Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract.
Kim IE; Amin A; Wang LJ; Cheng L; Perrino CM
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):687-693. PubMed ID: 31876605
[TBL] [Abstract][Full Text] [Related]
11. Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience.
Rodriguez EF; Fite JJ; Chowsilpa S; Maleki Z
Hum Pathol; 2019 Mar; 85():128-135. PubMed ID: 30502379
[TBL] [Abstract][Full Text] [Related]
12. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity.
Rooper LM; Sharma R; Li QK; Illei PB; Westra WH
Am J Surg Pathol; 2017 Nov; 41(11):1561-1569. PubMed ID: 28719469
[TBL] [Abstract][Full Text] [Related]
13. Comparison of INSM1 immunostaining with established neuroendocrine markers synaptophysin and chromogranin A in over 14,000 neuroendocrine and non-neuroendocrine tumors.
Möller K; Uhlig R; Gorbokon N; Dum D; Menz A; Büscheck F; Luebke AM; Hube-Magg C; Hinsch A; Höflmayer D; Fraune C; Lebok P; Weidemann S; Lennartz M; Jacobsen F; Clauditz TS; Steurer S; Burandt E; Krech R; Krech T; Marx AH; Sauter G; Simon R; Bernreuther C; Minner S
Mol Cell Endocrinol; 2024 Feb; 581():112106. PubMed ID: 37951531
[TBL] [Abstract][Full Text] [Related]
14. A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases.
Leblebici C; Yeni B; Savli TC; Aydın Ö; Güneş P; Cinel L; Şimşek BÇ; Yıldız P; Tuncel D; Kayahan S
Ann Diagn Pathol; 2019 Jun; 40():53-58. PubMed ID: 31031215
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Utility of INSM1 in Medullary Thyroid Carcinoma.
Seok JY; Kang M; De Peralta-Venturina M; Fan X
Int J Surg Pathol; 2021 Sep; 29(6):615-626. PubMed ID: 33650906
[TBL] [Abstract][Full Text] [Related]
16. Syntaxin-1 and Insulinoma-Associated Protein 1 Expression in Breast Neoplasms with Neuroendocrine Features.
Turkevi-Nagy S; Báthori Á; Böcz J; Krenács L; Cserni G; Kővári B
Pathol Oncol Res; 2021; 27():1610039. PubMed ID: 34764822
[No Abstract] [Full Text] [Related]
17. A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases.
Kuji S; Watanabe R; Sato Y; Iwata T; Hirashima Y; Takekuma M; Ito I; Abe M; Nagashio R; Omae K; Aoki D; Kameya T
Gynecol Oncol; 2017 Feb; 144(2):384-390. PubMed ID: 27908529
[TBL] [Abstract][Full Text] [Related]
18. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor.
Tanigawa M; Nakayama M; Taira T; Hattori S; Mihara Y; Kondo R; Kusano H; Nakamura K; Abe Y; Ishida Y; Okabe Y; Hisaka T; Okuda K; Fujino K; Ito T; Kawahara A; Naito Y; Yamaguchi R; Akiba J; Akagi Y; Yano H
Med Mol Morphol; 2018 Mar; 51(1):32-40. PubMed ID: 28849340
[TBL] [Abstract][Full Text] [Related]
19. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate.
Xin Z; Zhang Y; Jiang Z; Zhao L; Fan L; Wang Y; Xie S; Shangguan X; Zhu Y; Pan J; Liu Q; Huang Y; Dong B; Xue W
Hum Pathol; 2018 Sep; 79():151-159. PubMed ID: 29885405
[TBL] [Abstract][Full Text] [Related]
20. Insulinoma-associated protein 1 is a prognostic biomarker in pulmonary high-grade neuroendocrine carcinoma.
Minami K; Jimbo N; Tanaka Y; Ogawa H; Hokka D; Nishio W; Yoshimura M; Itoh T; Maniwa Y
J Surg Oncol; 2020 Aug; 122(2):243-253. PubMed ID: 32346887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
